166 related articles for article (PubMed ID: 38668220)
1. Physiochemical Characterization of Lipidic Nanoformulations Encapsulating the Antifungal Drug Natamycin.
Talarico L; Clemente I; Gennari A; Gabbricci G; Pepi S; Leone G; Bonechi C; Rossi C; Mattioli SL; Detta N; Magnani A
Nanomaterials (Basel); 2024 Apr; 14(8):. PubMed ID: 38668220
[TBL] [Abstract][Full Text] [Related]
2. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization.
Khames A; Khaleel MA; El-Badawy MF; El-Nezhawy AOH
Int J Nanomedicine; 2019; 14():2515-2531. PubMed ID: 31040672
[TBL] [Abstract][Full Text] [Related]
3. Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics.
Mascarenhas M; Chaudhari P; Lewis SA
Adv Ther; 2023 Aug; 40(8):3332-3359. PubMed ID: 37289410
[TBL] [Abstract][Full Text] [Related]
4. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency.
Chandasana H; Prasad YD; Chhonker YS; Chaitanya TK; Mishra NN; Mitra K; Shukla PK; Bhatta RS
Int J Pharm; 2014 Dec; 477(1-2):317-25. PubMed ID: 25455776
[TBL] [Abstract][Full Text] [Related]
5. Fabrication of carboxymethyl chitosan films for cheese packaging containing gliadin-carboxymethyl chitosan nanoparticles co-encapsulating natamycin and theaflavins.
Fang M; Wang J; Fang S; Zuo X
Int J Biol Macromol; 2023 Aug; 246():125685. PubMed ID: 37406906
[TBL] [Abstract][Full Text] [Related]
6. Dual Drug Loaded Lipid Nanocarrier Formulations for Topical Ocular Applications.
Youssef AAA; Dudhipala N; Majumdar S
Int J Nanomedicine; 2022; 17():2283-2299. PubMed ID: 35611213
[TBL] [Abstract][Full Text] [Related]
7. Natamycin sequesters ergosterol and interferes with substrate transport by the lysine transporter Lyp1 from yeast.
Szomek M; Reinholdt P; Walther HL; Scheidt HA; Müller P; Obermaier S; Poolman B; Kongsted J; Wüstner D
Biochim Biophys Acta Biomembr; 2022 Nov; 1864(11):184012. PubMed ID: 35914570
[TBL] [Abstract][Full Text] [Related]
8. Natamycin interferes with ergosterol-dependent lipid phases in model membranes.
Akkerman V; Scheidt HA; Reinholdt P; Bashawat M; Szomek M; Lehmann M; Wessig P; Covey DF; Kongsted J; Müller P; Wüstner D
BBA Adv; 2023; 4():100102. PubMed ID: 37691996
[TBL] [Abstract][Full Text] [Related]
9. Enhanced in vivo antifungal activity of novel cell penetrating peptide natamycin conjugate for efficient fungal keratitis management.
Rohira H; Shankar S; Yadav S; Shah SG; Chugh A
Int J Pharm; 2021 May; 600():120484. PubMed ID: 33737097
[TBL] [Abstract][Full Text] [Related]
10. The preparation and therapeutic effects of β-glucan-specific nanobodies and nanobody-natamycin conjugates in fungal keratitis.
Liu X; Sui J; Li C; Wang Q; Peng X; Meng F; Xu Q; Jiang N; Zhao G; Lin J
Acta Biomater; 2023 Oct; 169():398-409. PubMed ID: 37579912
[TBL] [Abstract][Full Text] [Related]
11. Antifungal Combination Eye Drops for Fungal Keratitis Treatment.
Díaz-Tomé V; Bendicho-Lavilla C; García-Otero X; Varela-Fernández R; Martín-Pastor M; Llovo-Taboada J; Alonso-Alonso P; Aguiar P; González-Barcia M; Fernández-Ferreiro A; Otero-Espinar FJ
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678663
[TBL] [Abstract][Full Text] [Related]
12. Cyclodextrin⁻Amphiphilic Copolymer Supramolecular Assemblies for the Ocular Delivery of Natamycin.
Lorenzo-Veiga B; Sigurdsson HH; Loftsson T; Alvarez-Lorenzo C
Nanomaterials (Basel); 2019 May; 9(5):. PubMed ID: 31096569
[TBL] [Abstract][Full Text] [Related]
13. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies.
Bhatta RS; Chandasana H; Chhonker YS; Rathi C; Kumar D; Mitra K; Shukla PK
Int J Pharm; 2012 Aug; 432(1-2):105-12. PubMed ID: 22569234
[TBL] [Abstract][Full Text] [Related]
14. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane.
te Welscher YM; ten Napel HH; Balagué MM; Souza CM; Riezman H; de Kruijff B; Breukink E
J Biol Chem; 2008 Mar; 283(10):6393-401. PubMed ID: 18165687
[TBL] [Abstract][Full Text] [Related]
15. Nanomicelles empower natamycin in treating fungal keratitis: An in vitro, ex vivo and in vivo study.
Sathe P; Kailasam V; Nagarjuna V; Sharma H; Velpandian T; Garg P; Nirmal J
Int J Pharm; 2024 May; 656():124118. PubMed ID: 38615806
[TBL] [Abstract][Full Text] [Related]
16. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies.
El-Nabarawi MA; Abd El Rehem RT; Teaima M; Abary M; El-Mofty HM; Khafagy MM; Lotfy NM; Salah M
Drug Dev Ind Pharm; 2019 Jun; 45(6):922-936. PubMed ID: 30744431
[TBL] [Abstract][Full Text] [Related]
17. Reduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution.
Guo Y; Karimi F; Fu Q; G Qiao G; Zhang H
Expert Opin Drug Deliv; 2020 Mar; 17(3):407-421. PubMed ID: 32009483
[No Abstract] [Full Text] [Related]
18. Topical chlorhexidine 0.2% versus topical natamycin 5% for fungal keratitis in Nepal: rationale and design of a randomised controlled non-inferiority trial.
Hoffman JJ; Yadav R; Das Sanyam S; Chaudhary P; Roshan A; Singh SK; Arunga S; Matayan E; Macleod D; Weiss HA; Leck A; Hu V; Burton MJ
BMJ Open; 2020 Sep; 10(9):e038066. PubMed ID: 32998924
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of colloidal stable gliadin-casein nanoparticles for the encapsulation of natamycin: Molecular interactions and antifungal application on cherry tomato.
Wu X; Hu Q; Liang X; Fang S
Food Chem; 2022 Oct; 391():133288. PubMed ID: 35623282
[TBL] [Abstract][Full Text] [Related]
20. Medical interventions for fungal keratitis.
FlorCruz NV; Evans JR
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD004241. PubMed ID: 25855311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
